S&P 500   3,351.42 (+1.61%)
DOW   27,677.57 (+1.85%)
QQQ   275.14 (+1.32%)
AAPL   113.41 (+1.01%)
MSFT   209.51 (+0.81%)
FB   256.61 (+0.70%)
GOOGL   1,456.25 (+1.19%)
AMZN   3,146.69 (+1.67%)
TSLA   420.59 (+3.25%)
NVDA   515.22 (+0.05%)
BABA   276.05 (+1.83%)
CGC   14.37 (+1.41%)
GE   6.26 (+2.45%)
MU   49.57 (+0.88%)
AMD   78.94 (+1.13%)
T   28.47 (+1.53%)
F   6.69 (+2.76%)
ACB   4.86 (-3.76%)
GILD   62.70 (+0.72%)
NFLX   482.07 (-0.17%)
DIS   126.21 (+1.78%)
BA   165.91 (+6.33%)
BAC   24.13 (+2.72%)
S&P 500   3,351.42 (+1.61%)
DOW   27,677.57 (+1.85%)
QQQ   275.14 (+1.32%)
AAPL   113.41 (+1.01%)
MSFT   209.51 (+0.81%)
FB   256.61 (+0.70%)
GOOGL   1,456.25 (+1.19%)
AMZN   3,146.69 (+1.67%)
TSLA   420.59 (+3.25%)
NVDA   515.22 (+0.05%)
BABA   276.05 (+1.83%)
CGC   14.37 (+1.41%)
GE   6.26 (+2.45%)
MU   49.57 (+0.88%)
AMD   78.94 (+1.13%)
T   28.47 (+1.53%)
F   6.69 (+2.76%)
ACB   4.86 (-3.76%)
GILD   62.70 (+0.72%)
NFLX   482.07 (-0.17%)
DIS   126.21 (+1.78%)
BA   165.91 (+6.33%)
BAC   24.13 (+2.72%)
S&P 500   3,351.42 (+1.61%)
DOW   27,677.57 (+1.85%)
QQQ   275.14 (+1.32%)
AAPL   113.41 (+1.01%)
MSFT   209.51 (+0.81%)
FB   256.61 (+0.70%)
GOOGL   1,456.25 (+1.19%)
AMZN   3,146.69 (+1.67%)
TSLA   420.59 (+3.25%)
NVDA   515.22 (+0.05%)
BABA   276.05 (+1.83%)
CGC   14.37 (+1.41%)
GE   6.26 (+2.45%)
MU   49.57 (+0.88%)
AMD   78.94 (+1.13%)
T   28.47 (+1.53%)
F   6.69 (+2.76%)
ACB   4.86 (-3.76%)
GILD   62.70 (+0.72%)
NFLX   482.07 (-0.17%)
DIS   126.21 (+1.78%)
BA   165.91 (+6.33%)
BAC   24.13 (+2.72%)
S&P 500   3,351.42 (+1.61%)
DOW   27,677.57 (+1.85%)
QQQ   275.14 (+1.32%)
AAPL   113.41 (+1.01%)
MSFT   209.51 (+0.81%)
FB   256.61 (+0.70%)
GOOGL   1,456.25 (+1.19%)
AMZN   3,146.69 (+1.67%)
TSLA   420.59 (+3.25%)
NVDA   515.22 (+0.05%)
BABA   276.05 (+1.83%)
CGC   14.37 (+1.41%)
GE   6.26 (+2.45%)
MU   49.57 (+0.88%)
AMD   78.94 (+1.13%)
T   28.47 (+1.53%)
F   6.69 (+2.76%)
ACB   4.86 (-3.76%)
GILD   62.70 (+0.72%)
NFLX   482.07 (-0.17%)
DIS   126.21 (+1.78%)
BA   165.91 (+6.33%)
BAC   24.13 (+2.72%)
Log in
NASDAQ:JNCE

Jounce Therapeutics Short Interest Ratio and Short Volume

$8.09
-0.14 (-1.70 %)
(As of 09/28/2020 11:28 AM ET)
Add
Compare
Today's Range
$8.09
Now: $8.09
$8.50
50-Day Range
$4.67
MA: $6.48
$10.95
52-Week Range
$2.79
Now: $8.09
$11.72
Volume11,721 shs
Average Volume646,611 shs
Market Capitalization$275.61 million
P/E Ratio13.05
Dividend YieldN/A
Beta2.11

Short Interest

Jounce Therapeutics (NASDAQ:JNCE) Short Interest Data

Current Short Volume:1,320,000 shares
Previous Short Volume:2,140,000 shares
Change Vs. Previous Month:-38.32%
Dollar Volume Sold Short:$10.86 million
Short Interest Ratio / Days to Cover:1.0
Last Record Date:September, 15 2020
Outstanding Shares:32,970,000 shares
Float Size:16,520,000 shares
Short Percent of Float:7.99%
Today's Trading Volume:11,721 shares
Average Trading Volume:646,611 shares
Today's Volume Vs. Average:-98.19%



Jounce Therapeutics (NASDAQ:JNCE) Short Interest History

DateShares Sold ShortDollar Volume Sold ShortPercentage ChangePercentage FloatDays to CoverPrice on Record Date
9/15/20201,320,000 $10.86 million -38.3%8.0%1.1$8.23
8/31/20202,140,000 $17.44 million -1.4%13.0%2.2$8.15
8/14/20202,170,000 $16.34 million -2.7%13.2%9.5$7.53
7/31/20202,230,000 $10.77 million 0.9%13.5%9.1$4.83
7/15/20202,210,000 $10.12 million 39.9%13.4%8.5$4.58
6/30/20201,580,000 $7.68 million 9.0%9.6%5.9$4.86
6/15/20201,450,000 $9.76 million -1.4%8.8%5.2$6.73
5/29/20201,470,000 $10.13 million -27.9%8.9%4.9$6.89
5/15/20202,040,000 $11.00 million -1.0%12.4%6.3$5.39
4/30/20202,060,000 $11.72 million 3.0%12.5%5.8$5.69
4/15/20202,000,000 $9.82 million -11.9%12.3%5.3$4.91
3/31/20202,270,000 $10.62 million 4.5%13.9%5.4$4.68
3/13/20202,171,400 $10.31 million -4.8%13.3%5.9$4.75
2/28/20202,280,000 $9.51 million -1.7%14.0%3.8$4.17
2/14/20202,320,000 $9.63 million 0.0%15.0%3$4.15
1/31/20202,320,000 $12.27 million 5.5%15.0%3$5.29
1/15/20202,200,000 $13.66 million 25.0%14.1%3.1$6.21
12/31/20191,760,000 $11.11 million 15.0%11.3%2.6$6.31
8/15/2019533,900 $1.99 million 19.0%3.7%2.9$3.73

Jounce Therapeutics (NASDAQ:JNCE) Short Interest FAQ

speech bubbles
speech bubbles











What is Jounce Therapeutics' current short interest?

Short interest is the volume of Jounce Therapeutics shares that have been sold short but have not yet been closed out or covered. As of September 15th, investors have sold 1,320,000 shares of JNCE short. 7.99% of Jounce Therapeutics' shares are currently sold short. View details.

What is a good short interest ratio for Jounce Therapeutics?

The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. Jounce Therapeutics currently has a short interest ratio of 1.0.

What is a good short interest percentage for Jounce Therapeutics?

Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 7.99% of Jounce Therapeutics' floating shares are currently sold short.

Is Jounce Therapeutics' short interest increasing or decreasing?

Jounce Therapeutics saw a decline in short interest in the month of September. As of September 15th, there was short interest totaling 1,320,000 shares, a decline of 38.3% from the previous total of 2,140,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment.

What is Jounce Therapeutics' float size?

Jounce Therapeutics currently has issued a total of 34,068,000 shares. Some of Jounce Therapeutics' outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Jounce Therapeutics currently has a public float of 16,520,000 shares.

How does Jounce Therapeutics' short interest compare to its competitors?

7.99% of Jounce Therapeutics' shares are currently sold short. Here is how the short interest of companies in the industry of "biological products, except diagnostic" compare to Jounce Therapeutics: Compugen Ltd. (0.00%), Regenxbio Inc (13.50%), Adaptimmune Therapeutics PLC - (0.00%), Translate Bio Inc (0.00%), Atara Biotherapeutics Inc (0.00%), Alector Inc (15.06%), Adverum Biotechnologies Inc (0.00%), Replimune Group Inc (3.52%), Vericel Corp (0.00%), and Krystal Biotech Inc (12.43%).

Which stocks are the most shorted right now?

As of the most recent reporting period, the following stocks had the largest short interest positions: Charter Communications Inc ($5.17 billion), Aon PLC ($3.57 billion), ViacomCBS Inc. ($3.01 billion), Clorox Co ($2.91 billion), Charles Schwab Co. ($2.80 billion), Mercadolibre Inc ($2.33 billion), Analog Devices, Inc. ($2.14 billion), Kroger Co ($1.99 billion), Moderna Inc ($1.96 billion), and Simon Property Group Inc ($1.80 billion). View all of the most shorted stocks.

What does it mean to sell short Jounce Therapeutics stock?

Short selling JNCE is an investing strategy that aims to generate trading profit from Jounce Therapeutics as its price is falling. Jounce Therapeutics' stock is trading down $0.14 today. To short Jounce Therapeutics stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that Jounce Therapeutics will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

How does a short squeeze work against Jounce Therapeutics?

A short squeeze for Jounce Therapeutics occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of JNCE, which in turn drives the price of the stock up even further.

How often is Jounce Therapeutics' short interest reported?

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including JNCE, twice per month. The most recent reporting period available is September, 15 2020.


This page was last updated on 9/28/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.